|
|||||
|
|
| rIL－2／LAK细胞治疗晚期恶性肿瘤 | |
| 引用本文： | 张月桂,刘军,唐亚莉,李殿俊,龙庆山,薛英威,王贵奇,赵家宏. rIL－2／LAK细胞治疗晚期恶性肿瘤[J]. 肿瘤防治研究, 1995, 0(1) |
| 作者姓名： | 张月桂 刘军 唐亚莉 李殿俊 龙庆山 薛英威 王贵奇 赵家宏 |
| 作者单位： | 黑龙江省肿瘤研究所，黑龙江省肿瘤医院 |
| 摘 要： | 胎儿来源的ＬＡＫ细胞／ｒＩＬ－２对５例失去手术、化疗、放疗机会的晚期恶性肿瘤病人进行了过继免疫治疗。结果都取得了一定的疗效，黑色素瘤病人肺转移结节基本消失，局部瘤细胞全部坏死，组织细胞正常；淋巴瘤病人转移灶消退５９％；小肠平滑肌肉瘤病人在没进行此疗法之前２年半复发、手术三次。第三次手术后用此疗法治疗一个疗程，三年后第一次复发。为晚期恶性肿瘤病人延长了生命，提高了生存质量争得了再次治疗的机会。 |
| 关 键 词： | 基因重组白细胞介素2（rIL－2）；淋巴因子激活的杀伤细胞（LAK）；癌免疫过继疗法；胎儿 |
Treatment of Patients with Advanced Malignant Tumor by Transfor LAK Cells Combined with rIL-2 |
|
| Zhang Yue-gui,et al. Treatment of Patients with Advanced Malignant Tumor by Transfor LAK Cells Combined with rIL-2[J]. Cancer Research on Prevention and Treatment, 1995, 0(1) | |
| Authors: | Zhang Yue-gui et al |
| Affiliation: | Cancer Institute: Helongjiang Harbin 150040 |
| Abstract: | Five advanced malignant tumor were treated with LAK cells isolated from human fetal spleen combined with rIL-2. One patient with malignant melanoma had metastasis tumor dispeared in one lung and significantly reduced in the other. The matastasis lesion of one patient with lymphoma decreased 59% after treatment, a patient with intestinal smooth muscle sarcoma had prolonged relapse by administrated LAK/rIL-2. NO serious effects were observed.The results indicated that LAK/ rIL-2 in the treatment of patient with advanced malignant tumor is effect and safe. |
| Keywords: | Lympboma-activated kill cell (LAK cell) Recombined interleukin-2 (rIL-2) Fatal Immunotherapy |
| 本文献已被 CNKI 等数据库收录！ | |